Exosome injection shows promise for liver failure in small trial
NCT ID NCT07409259
First seen Feb 17, 2026 · Last updated May 16, 2026 · Updated 12 times
Summary
This study tests whether adding PT-MSCs exosome injections to standard care can help people with acute-on-chronic liver failure live longer. Twenty adults aged 18–65 will receive either standard treatment alone or standard treatment plus four exosome infusions over 10 days. The main goal is to check safety and see if the treatment improves 12-week survival and liver function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE-ON-CHRONIC LIVER FAILURE (ACLF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Third Affiliated Hospital, Sun Yat-sen University Guangzhou, Guangdong, China 510630
Guangzhou, Guangdong, 510630, China
Conditions
Explore the condition pages connected to this study.